UNIVERSITY OF CINCINNATI
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1819-01-01
- Employees
- 5.9K
- Market Cap
- -
- Website
- https://www.uc.edu/
Clinical Trials
310
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (254 trials with phase data)• Click on a phase to view related trials
Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
- Conditions
- Radiation Injuries
- Interventions
- Biological: Pendulum Glucose Control (PGC)
- First Posted Date
- 2025-11-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT07231588
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck CancerRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Radiation: Proton therapy
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT07213934
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Image Detection of Impaired Microcirculatory Reperfusion
- Conditions
- Ischemic Stroke, AcuteLarge Vessel Occlusion
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT07099599
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Gender-affirming Voice Training With Visual Feedback
- Conditions
- Transgender WomenVoice Alteration
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 6
- Registration Number
- NCT07017595
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia
- Conditions
- Eldery PeopleCognitive DeclineMemory DeclineDHA CNS Delivery
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 153
- Registration Number
- NCT06933095
- Locations
- 🇺🇸
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 62
- Next
News
AM-101 Enhances Radiation Therapy Efficacy in Lung Cancer with Brain Metastasis
Researchers have discovered that AM-101, a synthetic benzodiazepine analog, can enhance the efficacy of radiation therapy for lung cancer that has metastasized to the brain.
Progesterone Drug Provera Linked to Vision Loss in Meningioma Patients
A recent study identifies progesterone, specifically Provera, as a significant risk factor for vision loss related to meningiomas in premenopausal women.
Alzheimer's Drugs May Work by Boosting Healthy Amyloid Beta Protein, Study Suggests
• New research suggests Alzheimer's drugs like lecanemab and donanemab may slow disease progression by increasing levels of healthy amyloid beta (Aβ42) protein in the brain. • The study challenges the prevailing theory that these drugs work solely by reducing toxic amyloid plaques, highlighting the potential importance of soluble Aβ42 in maintaining brain health. • Researchers analyzed data from nearly 26,000 patients, finding that increased levels of soluble Aβ42 correlated with slower Alzheimer's progression during treatment with these monoclonal antibodies. • The study authors propose alternative therapies focused on boosting soluble Aβ42 levels directly, rather than solely targeting amyloid plaques, which may have long-term risks.